Radotinib

Radotinib, sold under the brand name Supect, is an oral medication used to treat a specific type of leukemia. It is a Bcr-Abl tyrosine kinase inhibitor that selectively inhibits the Bcr-Abl tyrosine kinase, the abnormal fusion protein expressed in Philadelphia chromosome-positive chronic myeloid leukemia, and it also inhibits the platelet-derived growth factor receptor, suppressing the proliferation of leukemic cells. It is indicated for adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase who are resistant or intolerant to first-generation tyrosine kinase inhibitors such as imatinib. It received regulatory approval in South Korea in 2012 and, as of the source's most recent update, remains unapproved by the United States FDA or the European Medicines Agency, with its use limited to South Korea.